Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 3/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 5/20 | 0.37 |
| ▸ | MMP3 | P08254 | 5/20 | 0.37 |
| ▸ | MMP1 | P03956 | 3/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387040 | 1.00 | BMP1 (0.40) | BMP1SLC22A6TDP1ALDH1A1LMNA | |
| SCHEMBL24312057 | 0.81 | MMP2 (0.32) | BMP1TDP1ALDH1A1LMNAMAPT | |
| SCHEMBL13058954 | 0.80 | ALDH1A1 (0.48) | TDP1ALDH1A1MMP2MMP3MMP1 | |
| SCHEMBL27578968 | 0.80 | TSHR (0.46) | BMP1SLC22A6TDP1ALDH1A1LMNA | |
| SCHEMBL25773392 | 0.80 | MMP9 (0.37) | BMP1TDP1ALDH1A1LMNAMAPT | |
| SCHEMBL14355660 | 0.78 | MME (0.38) | SLC22A6TDP1ALDH1A1LMNAMAPT | |
| SCHEMBL19704970 | 0.78 | ECE1 (0.39) | BMP1MMP2MMP3MMP1 | |
| SCHEMBL19194706 | 0.78 | MME (0.38) | SLC22A6TDP1ALDH1A1LMNAMAPT | |
| SCHEMBL9911498 | 0.78 | MME (0.38) | SLC22A6TDP1ALDH1A1LMNAMAPT | |
| SCHEMBL13697033 | 0.78 | HIF1A (0.40) | SLC22A6TDP1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110905-A1 | ANTI-CEA ANTIBODY DRUG CONJUGATES AND METHODS OF USE | BEIGENE, LTD. (KY) | 2024-05-30 | — | — | WO | disclosed |
| EP-4289857-A1 | DRUG CONJUGATE OF GLUCOCORTICOID RECEPTOR AGONIST, AND APPLICATION THEREOF IN MEDICINE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023215740-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS, INC. (FR) | 2023-10-26 | — | — | US | disclosed |
| WO-2023178641-A1 | DNA TOXIC DIMER COMPOUND AND CONJUGATE THEREOF | 成都百利多特生物药业有限责任公司 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023125530-A1 | ANTIBODY DRUG CONJUGATES | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230190966-A1 | COMPOSITIONS USEFUL FOR TREATING GM1 GANGLIOSIDOSIS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-06-22 | — | — | US | disclosed |
| US-20090151944-A1 | Use of Polyimides in Treating Subterranean Formations | SCHLUMBERGER TECHNOLOGY CORPORATION | 2009-06-18 | — | — | US | disclosed |
| EP-1803780-B1 | Contrast dyes for inkjet lithographic printing plates | AGFA GRAPHICS NV (BE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080261849-A1 | Composition | RECKITT BENCKISER N.V. (NL) | 2008-10-23 | — | — | US | disclosed |
| US-20080146771-A1 | Maleamic acid polymer derivatives and their bioconjugates | NEKTAR THERAPEUTICS | 2008-06-19 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| EP-1803780-A1 | Contrast dyes for inkjet lithographic printing plates | Agfa Graphics N.V. (BE) | 2007-07-04 | — | — | EP | disclosed |
| US-20070104757-A1 | LATENT REACTIVE BLOOD COMPATIBLE AGENTS | Surmodics Coatings, LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070082022-A1 | LATENT REACTIVE BLOOD COMPATIBLE AGENTS | Surmodics Coatings, LLC | 2007-04-12 | — | — | US | disclosed |
| US-20070039365-A1 | Slow-release fertilizer and method of making and using same | REGAL CHEMICAL COMPANY | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | BMP1 382/4885SLC22A6 377/4885TDP1 2639/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | BMP1 2231/4885SLC22A6 1836/4885TDP1 543/4885 |
| US-20230190966-A1 | COMPOSITIONS USEFUL FOR TREATING GM1 GANGLIOSIDOSIS | GALC, GBA1, GBA2 | BMP1 2860/4885SLC22A6 649/4885TDP1 1020/4885 |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | CD44, FOLR1, CD47 | BMP1 3018/4885SLC22A6 1764/4885TDP1 926/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | BMP1 2081/4885SLC22A6 1520/4885TDP1 2265/4885 |
| US-20070082022-A1 | LATENT REACTIVE BLOOD COMPATIBLE AGENTS | FGB, HLA-A, HLA-C | BMP1 1218/4885SLC22A6 3163/4885TDP1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.